ALT
NASDAQ · Biotechnology
Altimmune Inc
$3.09
+0.05 (+1.64%)
Financial Highlights (FY 2026)
Revenue
97.2K
Net Income
-194,335,742
Gross Margin
100.5%
Profit Margin
-214,861.0%
Rev Growth
—
D/E Ratio
0.15
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.5% | 100.5% | 63.1% | 63.1% |
| Operating Margin | -230,461.0% | -464,274.5% | 8.7% | 10.0% |
| Profit Margin | -214,861.0% | -451,530.3% | 8.8% | 7.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 97.2K | 232.2K | 252.74M | 265.40M |
| Gross Profit | 97.6K | 233.3K | 159.59M | 167.58M |
| Operating Income | -223,955,066 | -1,077,929,211 | 21.93M | 26.57M |
| Net Income | -194,335,742 | -932,514,656 | 22.15M | 19.00M |
| Gross Margin | 100.5% | 100.5% | 63.1% | 63.1% |
| Operating Margin | -230,461.0% | -464,274.5% | 8.7% | 10.0% |
| Profit Margin | -214,861.0% | -451,530.3% | 8.8% | 7.2% |
| Rev Growth | — | -83.5% | +1.7% | -9.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 39.73M | 0 | 46.99M | 48.17M |
| Total Equity | 260.55M | — | 234.58M | 252.01M |
| D/E Ratio | 0.15 | — | 0.20 | 0.19 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -208,620,848 | -1,065,342,972 | 31.01M | 30.68M |
| Free Cash Flow | — | — | 16.83M | 21.60M |